Posaconazole: a new option for invasive fungal infection management

Published: June 8, 2009
Abstract Views: 214
PDF: 599
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

For most of the last 50 years, antifungal therapy has relied on amphotericin B deoxycholate. The emergence of lipid-based amphotericin B formulations rendered a significant advance in terms of reducing toxicity, although they are still associated with renal and hepatic damage. During the late 1980s fluconazole became available. It was the first antifungal drug with an excellent safety profile, but its activity spectrum is limited. A new era in antifungal therapy began in the early 2000s with the advent of a new class of antifungal drugs, the echinocandins, with a wide activity spectrum and excellent tolerability.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Nosari, A. (2009). Posaconazole: a new option for invasive fungal infection management. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.416